natgillin/translations-raw huggingface dataset:
Pergoveris contains potent gonadotrophic substances capable of causing mild to severe adverse reactions, and should only be used by physicians who are thoroughly familiar with infertility problems and their management. 
Zdravilo Pergoveris vsebuje močni gonadotropni učinkovini, ki lahko povzročita blage do hude neželene učinke in ga zato smejo uporabljati samo zdravniki, ki dobro poznajo težave neplodnosti in njihovo obvladovanje.
Independent risk factors for developing OHSS include young age, lean body mass, polycystic ovarian syndrome, higher doses of exogenous gonadotrophins, high absolute or rapidly rising serum oestradiol level (> 900 pg/mL or > 3,300 pmol/L in anovulation), previous episodes of OHSS and large number of developing ovarian follicles (3 follicles of ≥ 14 mm in diameter in anovulation). 
Neodvisni dejavniki tveganja za razvoj OHSS vključujejo mladost, mršavo telesno maso, sindrom policističnih jajčnikov, večje odmerke eksogenih gonadotropinov, visoke absolutne ali hitro naraščajoče serumske koncentracije estradiola ( > 900 pg/ml ali > 3.300 pmol/l v anovulaciji), predhodnje epizode OHSS in veliko število razvijajočih se ovarijskih foliklov (3 folikle s premerom ≥ 14 mm v anovulaciji).
Elimination Total clearance is 0.6 L/h and one-eighth of the follitropin alfa dose is excreted in the urine. 
Izločanje Skupni očistek je 0,6 l/h in ena osmina odmerka folitropina alfa se izloči z urinom.
This could cause chest pain, breathlessness, stroke or heart attack. 
Povzročijo lahko bolečino v prsnem košu, zasoplost, kap ali srčni napad.
• If you administer Pergoveris to yourself, please carefully read and follow section “Instructions for Use”. 
• Če si zdravilo Pergoveris dajete sami, natančno preberite in upoštevajte poglavje „Navodila za uporabo“.
Following intravenous administration, lutropin alfa is rapidly distributed with an initial half-life of approximately one hour and eliminated from the body with a terminal half-life of about 10-12 hours. 
Po intravenskem dajanju se lutropin alfa hitro porazdeli z začetnim razpolovnim časom približno 1 uro in se izloči iz telesa s končnim razpolovnim časom približno 10-12 ur.
If you do not see a tiny drop(s) of fluid at or near the tip the first time you use a new pen: 
Če prvič ne opazite drobnih kapljic tekočine na konici ali blizu nje, uporabite nov napolnjeni injekcijski peresnik:
Self-administration should only be performed by patients who are well motivated, adequately trained and with access to expert advice. 
Samo bolniki, ki so dobro motivirani, ustrezno poučeni in imajo dostop do strokovnega nasveta, si lahko dajejo zdravilo sami.
This is when you have developed a suitable follicle, as assessed using ultrasound scans and blood tests. 
To je, ko se razvije ustrezen folikel, kot se oceni z ultrazvočnim slikanjem in krvnimi testi.
For instructions on the use of this medicinal product, see the package leaflet, section 'Instructions for use'. 
Za navodila o uporabi tega zdravila glejte poglavje „Navodila za uporabo“ v priloženem navodilu.
If your body responds too strongly, your treatment will be stopped and you will not be given any hCG (see in section 2. under ”Ovarian hyperstimulation syndrome (OHSS)”). 
Če se vaše telo čezmerno odzove, je treba vaše zdravljenje prekiniti in hCG ne boste dobili (glejte poglavje 2 „Sindrom hiperstimulacije jajčnikov (OHSS)“).
Warning: Do not recap the needle with the green inner shield, as it can lead to needle stick. 
Opozorilo: Injekcijske igle ne zapirajte z zelenim notranjim ščitnikom, saj se lahko z iglo zbodete.
Adherence to recommended Pergoveris and FSH dosage and regimen of administration can minimise the risk of ovarian hyperstimulation. 
Upoštevanje priporočenega odmerjanja zdravila Pergoveris in FSH in režima dajanja lahko zmanjšata tveganje hiperstimulacije jajčnikov.
Your ovaries may have over-reacted to the treatment and formed large sacs of fluid or cysts (see in section 2. under “Ovarian hyperstimulation syndrome (OHSS)”). 
Vaši jajčniki so se morda prekomerno odzvali na zdravljenje in razvile so se velike vrečke s tekočino ali ciste jajčnikov (glejte poglavje 2 pod „Sindrom hiperstimulacije jajčnikov (OHSS)“).
Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum. 
Pretehta naj se ali je potrebna podpora lutealne faze, ker pomanjkanje snovi z luteotropno aktivnostjo (LH/hCG) po ovulaciji lahko privede do prezgodnje odpovedi rumenega telesca.
Pergoveris is indicated for the stimulation of follicular development in adult women with severe LH and FSH deficiency. 
Zdravilo Pergoveris je indicirano za spodbujanje razvoja foliklov pri odraslih ženskah s hudim pomanjkanjem LH in FSH.
Following repeated administration, follitropin alfa accumulates 3-fold achieving a steady-state within 3-4 days. 
Po večkratnem dajanju, se folitropin alfa trikratno kopiči in doseže stanje dinamičnega ravnovesja v 3 do 4 dneh.
Do not use Pergoveris if you notice any visible signs of deterioration, if the liquid contains particles or is not clear. 
Ne uporabljajte zdravila Pergoveris, če opazite kakršne koli vidne znake kvarjenja, če raztopina vsebuje delce ali ni bistra.
• gynaecological haemorrhages of unknown origin 
• z ginekološkimi krvavitvami neznanega izvora;
A recommended regimen commences with one vial of Pergoveris daily. 
Priporočeni režim se začne z eno vialo zdravila Pergoveris na dan.
and show the dose of follitropin alfa. 
in prikazujejo odmerek folitropina alfa.
The usual starting dose is one vial of Pergoveris every day. 
Običajni začetni odmerek je ena viala zdravila Pergoveris vsak dan.
• The OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest. 
• OHSS lahko postane hud z izrazito povečanimi jajčniki, zmanjšanim nastajanjem urina, s pridobivanjem telesne mase, težavami dihanja in/ali morebitnim nabiranjem tekočine v trebuhu ali prsnem košu.
• local reactions at the injection site such as pain, itching, bruising, swelling or irritation. 
• lokalne reakcije na mestu injiciranja, kot so bolečina, srbenje, modrica, oteklina ali razdraženost
Other medicines and Pergoveris Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. 
Obvestite zdravnika ali farmacevta, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
• The Dose Feedback Window will indicate the missing amount you need to inject using a new pen. 
• Okence za prikaz odmerka prikazuje manjkajočo količino, ki jo morate injicirati z novim injekcijskim peresnikom.
There have been isolated reports of non-serious allergic reactions to Pergoveris. 
Obstajajo posamična poročila o neogrožajočih alergijskih reakcijah na zdravilo Pergoveris.
• Remove the syringe from the vial and set it down carefully. 
• Brizgo odstranite z viale in jo previdno odložite.
• if you have cancer in your ovaries, womb or breasts 
• če imate rak jajčnika, maternice ali dojke,
What Pergoveris is and what it is used for What you need to know before you use Pergoveris How to use Pergoveris 
Kaj je zdravilo Pergoveris in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Pergoveris Kako uporabljati zdravilo Pergoveris Možni neželeni učinki
c. Read the dose remaining to be injected with a second pen. 
c. Prebrati preostanek odmerka, ki ga je treba injicirati z drugim peresnikom.
If you are not sure, talk to your doctor, pharmacist or nurse before using this medicine. 
Če ste negotovi, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden uporabite to zdravilo.
Clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, or acute pulmonary distress, and thromboembolic events. 
Klinična ocena lahko razkrije hipovolemijo, hemokoncentracijo, elektrolitsko neravnovesje, ascites, hemoperitonej, plevralni izliv, hidrotoraks ali akutno respiratorno stisko in trombembolične dogodke.
• Remove the protective cap from the vial filled with water (solvent vial). 
• Odstranite zaščitno zaporko z viale z vodo (viala z vehiklom).
* produced in genetically engineered Chinese hamster ovary (CHO) cells. 
* pridobljen v jajčnih celicah kitajskih hrčkov (CHO), pridobljenih z genetskim inženiringom.
• Your doctor/pharmacist will tell you how many pens of Pergoveris you need to complete your treatment. 
• Zdravnik ali farmacevt vam bo povedal, koliko napolnjenih injekcijskih peresnikov zdravila Pergoveris potrebujete, da dokončate zdravljenje.
The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction than in the normal population. 
Pogostnost izgube nosečnosti zaradi spontanega splava ali abortusa je pri bolnicah, ki so v postopku stimulacije folikularne rasti za indukcijo ovulacije, večja kot pri normalni populaciji.
a. Dial your prescribed dose. 
a. Izbrati predpisani odmerek.
Once opened, the pre-filled pen may be stored for a maximum of 28 days outside of the refrigerator (at 25°C). 
Odprto napolnjeno injekcijsko pero lahko zunaj hladilnika shranjujete največ 28 dni (pri 25 °C).
For further instructions on reconstitution of the medicinal product before administration, see section 6.6. 
Za navodila glede rekonstitucije zdravila pred dajanjem glejte poglavje 6.6.
When a risk of OHSS is assumed, treatment discontinuation should be considered. 
V primeru domneve tveganja za OHSS je treba razmisliti o prekinitvi zdravljenja.
Therefore the product may not be stored once opened and reconstituted. 
Zato odprtega in rekonstituiranega zdravila ni dovoljeno shranjevati.
If less than one vial daily is used, the follicular response may be unsatisfactory because the amount of lutropin alfa may be insufficient (see section 5.1). 
Pri uporabi manj kot ene viale na dan, je lahko razvoj foliklov nezadosten zaradi premajhne količine lutropina alfa (glejte poglavje 5.1).
This instructions for use was last revised in: 
Navodilo je bilo nazadnje revidirano dne:
• According to your response, your doctor may decide to add every day a dose of a licensed follitropin alfa preparation to your Pergoveris injection. 
• Skladno z vašim odzivom se bo vaš zdravnik morda odločil, da vsak dan doda odmerek pripravka folitropina alfa z dovoljenjem za promet vaši injekciji zdravila Pergoveris.
Data on a limited number of exposed pregnancies indicate no adverse reactions of follitropin alfa and lutropin alfa on pregnancy, embryonal or foetal development, parturition or postnatal development following controlled ovarian stimulation. 
Podatki, zbrani pri majhnem številu nosečnic, ki so bile izpostavljene zdravilu, ne kažejo na možnost neželenih učinkov folitropina alfa in lutropina alfa na nosečnost, razvoj zarodka ali plodu, porod ali postnatalni razvoj po nadzorovani stimulaciji jajčnikov.
• Check that the peel-off seal on the outer needle cap is not damaged or loose (Fig.3). 
• Preverite, da lepljivi jeziček na zunanjem pokrovčku injekcijske igle ni poškodovan ali razrahljan (sl. 3):
Warning: Refer to the Package leaflet for more information on the recommended dose regimen and always follow the dose recommended by your doctor. 
Opozorilo: Za več informacij o priporočenem režimu odmerjanja glejte navodilo za uporabo in vedno upoštevajte zdravnikova priporočila o odmerjanju.
Thromboembolism, usually associated with severe OHSS Respiratory, thoracic and mediastinal disorders Very rare: 
trombembolija, običajno povezana s hudim OHSS Bolezni dihal, prsnega koša in mediastinalnega prostora Zelo redki:
Removing the needle after each injection. 
Odstranjevanje injekcijske igle po vsakem injiciranju.
• Remove the protective cap from the vial filled with Pergoveris powder. 
• Odstranite zaščitno zaporko z viale s praškom zdravila Pergoveris.
Tiny amounts of concentrated phosphoric acid and sodium hydroxide are added to keep acidity levels (pH levels) normal. 
Dodane so neznatne količine koncentrirane fosforjeve (V) kisline in natrijevega hidroksida za ohranjanje običajne ravni kislosti (ravni pH).
Pergoveris should be given as a course of daily injections. 
Zdravilo Pergoveris moramo dajati kot serijo vsakodnevnih injekcij.
Getting your Pergoveris pre-filled pen ready for injection 5.1. 
Priprava zdravila Pergoveris napolnjen injekcijski peresnik na injiciranje 5.1.
In patients undergoing induction of ovulation, the incidence of multiple pregnancies and births is increased compared with natural conception. 
Pri bolnicah v postopku indukcije ovulacije, je pogostnost večplodnih nosečnosti in porodov v primerjavi z naravno zanositvijo, povečana.
• Store the pen in its original packaging in a safe place and as indicated in the package leaflet. 
• Injekcijski peresnik shranjujte v originalni ovojnini na varnem mestu, kot je navedeno v navodilu za uporabo.
• ovarian, uterine or mammary carcinoma 
• z ovarijskim, materničnim karcinomom ali karcinomom dojke.
This may be associated with other risk factors such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovarian syndrome. 
To je lahko povezano z ostalimi dejavniki tveganja, kot so OHSS, nosečnost, predhodne operacije v trebušni votlini, torzija jajčnika v anamnezi, predhodna ali trenutna cista jajčnika ali sindrom policističnega jajčnika.
What Pergoveris is and what it is used for 
Kaj je zdravilo Pergoveris in za kaj ga uporabljamo
When using Pergoveris, you have a higher risk of being pregnant with more than one child at the same time (“multiple pregnancy”, mostly twins), than if you conceived naturally. 
Pri uporabi zdravila Pergoveris je tveganje za nosečnost z več plodi večja („večplodna nosečnost“, običajno dvojčki) kot pri naravni zanositvi.
• Only use the Pergoveris pre-filled pen if your healthcare provider trains you on how to use it correctly. 
• Zdravilo Pergoveris napolnjen injekcijski peresnik uporabljajte le, če vas je zdravstveni delavec naučil, kako ga pravilno uporabljati.
However this will only occur if hCG is administered (see in section 2. under “Ovarian hyperstimulation syndrome (OHSS)”). 
Vendar pa se to lahko pojavi samo, če se uporabi hCG (glejte poglavje 2 „Sindrom hiperstimulacije jajčnikov (OHSS)“).
Breast pain, pelvic pain, mild or moderate OHSS (including associated symptomatology) 
bolečine v prsnem košu, bolečine v medenici, blag do zmeren OHSS (vključno s povezanimi simptomi)
Take as much time as you need to inject all the solution. 
Vzemite si dovolj časa, da injicirate vso raztopino.
If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 7-14 day intervals and preferably by 37.5-75 IU increments using a licensed follitropin alfa preparation. 
Če se izkaže kot primerno povečanje odmerka FSH, moramo prilagoditev odmerka izvesti po možnosti v 7-14 dnevnih intervalih s povečanji po 37,5 i.e. do 75 i.e. z uporabo pripravka folitropina alfa z dovoljenjem za promet.
This syndrome occurs with higher incidence in patients with polycystic ovarian disease. 
Ta sindrom se pogosteje pojavi pri bolnicah s policističnimi jajčniki.
• The solvent is a clear colourless liquid in a glass vial containing1 mL of water for injections. 
• Vehikel je bistra brezbarvna tekočina v stekleni viali, ki vsebuje 1 ml vode za injiciranje.
There is no indication for the use of Pergoveris during pregnancy. 
Za uporabo zdravila Pergoveris med nosečnostjo ni indikacij.
When risk of multiple pregnancies is assumed, treatment discontinuation should be considered. 
V primeru domneve tveganja večplodnih nosečnosti je treba razmisliti o prekinitvi zdravljenja.
• sacs of fluid within the ovaries (ovarian cysts) 
• vrečke s tekočino v jajčnikih (ovarijske ciste)
• 1 vial containing Pergoveris powder • 1 vial containing water for injections (solvent) 
• 1 viala s praškom zdravila Pergoveris • 1 viala z vodo za injekcije (vehikel)
To minimise the risk of multiple pregnancy, ultrasound scans as well as blood tests are recommended. 
Za zmanjšanje tveganja večplodnih nosečnosti se priporočajo pregledi z ultrazvokom in krvni testi.
Amount to Be Set for a Second Injection 
Količina, ki jo nastavite za drugo injiciranje
In one clinical study of women with hypogonadotrophic hypogonadism and an endogenous serum LH concentration below 1.2 IU/L the appropriate dose of r-hLH was investigated. 
V klinični študiji z ženskami s hipogonadotropnim hipogonadizmom in endogeno koncentracijo LH manjšo od 1,2 i.e./l, so proučevali ustrezen odmerek r-hLH.
The lutropin alfa pharmacokinetics following single and repeated administration of lutropin alfa are comparable and the accumulation ratio of lutropin alfa is minimal. 
Farmakokinetika lutropina alfa po enkratnem in večkratnem dajanju lutropina alfa je primerljiva in stopnja akumulacije lutropina alfa je minimalna.
Check for particles as before, and do not use if the solution is not clear. 
Kot prej preverite, ali vsebuje delce, in raztopine ne uporabite,
In women whose endogenous gonadotrophin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels. 
Pri ženskah z zavrtim izločanjem endogenih gonadotropinov, je folitropin alfa vseeno učinkovito spodbujal razvoj foliklov in steroidogenezo, kljub nemerljivim ravnem LH.
• Immediately inject the solution. 
• Takoj injicirajte raztopino.
• if you have a condition that would make a normal pregnancy impossible, such as an early menopause, malformed sex organs or benign tumours of the womb. 
• če imate stanje, ki bi običajno onemogočala normalno nosečnost, kot so prezgodnja menopavza,
*recombinant human follitropin alfa and recombinant human lutropin alfa are produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. 
*rekombinantni humani folitropin alfa in rekombinantni humani lutropin alfa sta pridobljena iz celic jajčnikov kitajskega hrčka (CHO) s tehnologijo rekombinantne DNA.
Patients undergoing stimulation of follicular growth are at an increased risk of developing hyperstimulation in view of possible excessive oestrogen response and multiple follicular development. 
Pri bolnicah v postopku stimulacije folikularne rasti je povečano tveganje za razvoj hiperstimulacije, ki se lahko kaže kot pretiran estrogenski odziv in razvoj multiplih foliklov.
Do not use Pergoveris 
Ne uporabljajte zdravila Pergoveris
Verify that the Dose Feedback Window is set to "0". 
Prepričajte se, da je okno za prikaz odmerka nastavljeno na "0".
It comprises marked ovarian enlargement, high serum sex steroids, and an increase in vascular permeability which can result in an accumulation of fluid in the peritoneal, pleural and, rarely, in the pericardial cavities. 
Obsega izrazito povečanje jajčnikov, visoko serumsko raven spolnih steroidnih hormonov in povečano prepustnost žil, kar lahko rezultira v nabiranju tekočine v trebušni votlini, plevralni votlini in redko v osrčniku.
Clinical studies with Pergoveris were conducted with a freeze-dried formulation. 
Klinične študije z zdravilom Pergoveris so bile izvedene z liofiliziranim pripravkom.
• Remove the peel-off seal (Fig. 4). 
• Odstranite lepljivi jeziček (sl. 4).
Pergoveris is a preparation of recombinant human follicle stimulating hormone (follitropin alfa, r-hFSH) and recombinant human luteinising hormone (lutropin alfa, r-hLH) produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. 
Zdravilo Pergoveris je pripravek z rekombinantnim humanim stimulirajočim hormonom (folitropin alfa, r-hFSH) in rekombinantnim humanim luteinizirajočim hormonom (lutropin alfa, r-hLH), ki sta pridobljena v celicah jajčnika kitajskega hrčka (CHO - Chinese Hamster Ovary) s tehnologijo rekombinantne DNA.
• Pergoveris is intended to be given by injection just under the skin (subcutaneously). 
• Zdravilo Pergoveris se daje v obliki injekcije tik pod kožo (subkutano).
Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments. 
Pri ženskah z boleznijo jacevodov v anamnezi, obstaja tveganje zunajmaternične nosečnosti, ne glede na to ali pride do zanositve spontano ali z zdravljenjem neplodnosti.
Nevertheless there is a possibility that OHSS may occur, which is further described in section 4.4. 
Vendar pa lahko pričakujemo pojav sindroma hiperstimulacije jajčnikov, ki je podrobno opisan v poglavju 4.4.
Therefore, administration of less than one vial of Pergoveris daily may provide too little LH-activity to ensure adequate follicular development. 
Zato lahko dajanje manj kot ene viale zdravila Pergoveris dnevno, rezultira v premajhni aktivnosti LH za zagotovitev ustreznega razvoja foliklov.
They will supervise your first injection. 
Pri prvem injiciranju vas bodo nadzirali.
• Pergoveris is supplied in packs of 1, 3 and 10 vials of powder with the corresponding number of solvent's vials (1, 3 and 10 vials). 
• Zdravilo Pergoveris je na voljo v pakiranjih po 1, 3 in 10 vial s praškom z ustreznim številom vial vehikla (1, 3 in 10 ).
The medicine must be administered immediately after reconstitution. 
Zdravilo morate uporabiti takoj po pripravi.
In the stimulation of follicular development in anovulatory women deficient in LH and FSH, the primary effect resulting from administration of lutropin alfa is an increase in oestradiol secretion by the follicles, the growth of which is stimulated by FSH. 
Pri stimulaciji razvoja foliklov pri ženskah brez ovulacije s pomankanjem LH in FSH, je primarni učinek dajanja lutropina alfa povečanje izločanja estradiola iz foliklov, katerih rast je spodbujena z FSH.
Pergoveris is not indicated during breast-feeding. 
Zdravilo Pergoveris ni indicirano med dojenjem.
Women who have ever had blocked or damaged fallopian tubes (tubal disease) are at risk of pregnancy where the embryo is implanted outside the womb (ectopic pregnancy). 
Pri ženskah, ki so imele neprehodne ali poškodovane jajcevode (bolezen jajcevodov), obstaja tveganje nosečnosti, kjer se zarodek vgnezdi zunaj maternice (zunajmaternične nosečnosti).
Pharmacokinetic/pharmacodynamic relationships There is no pharmacokinetic interaction with follitropin alfa when administered simultaneously. 
Farmakokinetično/farmakodinamično razmerje Pri sočasnem dajanju s folitropinom alfa ni farmakokinetičnih interakcij.
No teratogenic effect of such gonadotropins has been reported in animal studies. 
Študije na živalih ne kažejo teratogenih učinkov takih gonadotropinov.
• A sharps disposal bin (not included in the pack) 
•vsebnik za odlaganje ostrih odpadkov (ni vključen v pakiranju).
For instructions on the use of this medicinal product, see section 6.6. 
Za navodila glede uporabe zdravila glejte poglavje 6.6.
Your doctor or nurse will have already advised you where to inject (e.g. tummy, front of thigh). 
Zdravnik ali medicinska sestra sta vas že poučila o mestu injiciranja injekcije (npr. v trebuh, sprednjo stran stegna).
There may be a degree of interpatient variability in response to FSH/LH administration, with a poor response to FSH/LH in some patients. 
Razpon odziva na zdravljenje s FSH/LH se lahko med bolnicami razlikuje, pri nekaterih bolnicah je odziv na dajanje FSH/LH zelo majhen.
In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of Pergoveris therapy is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotrophin (hCG). 
Pri ženskah s pomanjkanjem LH in FSH (hipogonadotropni hipogonadizem) je cilj zdravljenja z zdravilom Pergoveris razvoj enega samega dozorelega Graafovega folikla, iz katerega se bo po dajanju humanega horionskega gonadotropina (hCG-ja) sprostil oocit.
• Your doctor or nurse will show you how to use the Pergoveris pre-filled pen to inject the medicine. 
• Vaš zdravnik ali medicinska sestra vam bo pokazala, kako uporabiti zdravilo Pergoveris napolnjen injekcijski peresnik za injiciranje zdravila.